A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants

International Journal of Neuropsychopharmacology

Volumn 7, Issue 4, 2004, Pages 471-479

  Katz, Martin M ^a,g   Houston, John P ^b   Brannan, Steven ^c   Bowden, Charles L ^a   Berman, Nancy ^d   Swann, Alan C ^e   Frazer, Alan ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Cyberonics Inc   (Italy)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Behavioural components; Clinical trials; Multivantaged behavioural method; Onset of antidepressant action; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE;

ADULT; AFFECT; AGED; AGITATION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG MONITORING; FEMALE; HAMILTON SCALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RELIABILITY; SOMATIZATION;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 10644273589     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004407     Document Type: Article

References (29)

1. Croughan JL, Secunda SK, Katz MM, Robins E, Mendels J, Swann A, Harris-Larkin B (1988). Sociodemographic and prior clinical course characteristics associated with treatment response in depressed patients. Journal of Psychiatric Research 22, 227-237.
2. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L (1974). The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. In: Pichot P (Ed.), Psychological Measurements in Psychopharmacology: Modern Problems in Pharmacopsychiatry (pp. 79-110). Basel: Karger.
3. Endicott J, Spitzer R (1978). A diagnostic interview. The schedule for affective disorders and schizophrenia. Archives of General Psychiatry 34, 837-844.
4. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766-771.
5. Gelenberg AJ, Chesen CL (2000). How fast are antidepressants? Journal of Clinical Psychiatry 61, 712-721.
6. Gorman JM (2002). Treatment of generalized anxiety disorder. Journal of Clinical Psychiatry 63, 17-23.
7. Guy W (1976). Early clinical drug evaluation program (ECDEU). Assessment Manual of Psychopharmacology. Rockville MD, Department of Health, Education and Welfare.
8. Hamilton M (1960). A rating scale for depression. Journal of Neurology and Neurosurgery Psychiatry 23, 56-62.
9. Katz MM, Koslow SH, Berman N, Secunda S, Maas JW, Casper R, Kocsis J, Stokes P (1984). A multi-vantaged approach to measurement of behavioral and affect states for clinical and psychobiological research. Psycholological Reports 55, 619-671.
10. Katz MM, Koslow SH, Frazer A (1996/1997). Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depression and Anxiety 4, 257-267.
11. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R, Croughan J, Kocsis J, Redmond Jr. E (1987). The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychological Medicine 17, 297-309.
12. Katz MM, Maas JW, Frazer A, Koslow SH, Bowden CL, Berman N, Swann A, Stokes P (1994). Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology 11, 89-100.
13. Katz MM, Robins E, Croughan J, Secunda A, Swann A (1982). Behavioral measurement and drug response characteristics of unipolar and bipolar depression. Psychological Medicine 17, 297-309.
14. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29, 566-579.
15. Katz MM, Wetzler S, Koslow SH, Secunda S (1989). Video methodology in the study of the psychopathology and treatment of depression. Psychiatric Annals 19, 372-381.
16. Laird NM, Ware JH (1982). Random effects model for longitudinal data. Biometrics 38, 963-974.
17. Leon AC (2001). Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. Journal of Clinical Psychiatry 62 (Suppl. 4), 12-16.
18. Lydiard RB, Bobes J (2000). Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depression and Anxiety 11, 99-104.
19. Maas JW, Koslow S, Davis J, Katz MM, Mendels J, Robins E, Stokes P, Bowden C (1980). Biological component of the NIMH Clinical Research Branch Collaborative Program in the Psychobiology of Depression. I. Background, theoretical considerations. Psychological Medicine 10, 759-776.
20. Maas JW, Koslow SH, Katz MM, Gibbons RL, Bowden CL, Robins E, Davis JM (1984). Pretreatment neurotransmitter metabolites and tricyclic antidepressant drug response. American Journal of Psychiatry 141, 1159-1171.
21. Montgomery SA, Asberg MA (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
22. Montgomery SA, Bech P, Blier P, Moller Hj, Nierenberg AA, Finder RM, Quitkin FM, Reimitz PE, Rosenbaum JF, Rush AJ, Stassen HH, Thase ME (2002). Selecting methodologies for the evaluation of differences in time to response to antidepressants. Journal of Clinical Psychiatry 63, 694-699.
23. Parker G, Roy K, Menkes DB, Snowdon J, Boyce P, Grounds D, Hughson B, Stringer C (2000). How long does it take for antidepressant therapies to act? Australia and New Zealand Journal of Psychiatry 34, 65-70.
24. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350-357.
25. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior, and self-ratings of hospitalized depressives. Journal of Nervous and Mental Diseases 148, 87-98.
26. Redmond DE, Katz MM, Maas JW, Swann A, Casper R (1986). Cerebrospinal fluid biogenic amine metabolite relationships with behavioral measurements in unipolar and bipolar depressed, manic, and healthy control subjects. Archives of General Psychiatry 43, 938-947.
27. Stassen HH, Angst J, Delini-Stula A (1997). Delayed onset of action of antidepressant drugs? Survey of recent results. European Psychiatry 12, 166-176.
28. Stassen HH, Delini-Stula A, Angst J (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology 3, 127-135.
29. Swann AC, Koslow SH, Katz MM, Maas JW, Javaid J, Secunda SK, Robins E (1987). Lithium carbonate treatment of mania: cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Archives of General Psychiatry 44, 345-354.